The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
Open accessAbstract
Nicotinic acid is one of the most effective agents for both lowering triglycerides and raising HDL. However, the side effect of cutaneous flushing severely limits patient compliance. As nicotinic acid stimulates the GPCR GPR109A and Gi/Go proteins, here we dissected the roles of G proteins and the adaptor proteins, beta-arrestins, in nicotinic acid-induced signaling and physiological responses. In a human cell line-based signaling assay, nicotinic acid stimulation led to pertussis toxin-sensitive lowering of cAMP, recruitment of beta-arrestins to the cell membrane, an activating conformational change in beta-arrestin, and beta-arrestin-dependent signaling to ERK MAPK. In addition, we found that nicotinic acid promoted the binding of beta-arrestin1 to activated cytosolic phospholipase A2 as well as beta-arrestin1-dependent activation of cytosolic phospholipase A2 and release of arachidonate, the precursor of prostaglandin D2 and the vasodilator responsible for the flushing response. Moreover, beta-arrestin1-null mice displayed reduced cutaneous flushing in response to nicotinic acid, although the improvement in serum free fatty acid levels was similar to that observed in wild-type mice. These data suggest that the adverse side effect of cutaneous flushing is mediated by beta-arrestin1, but lowering of serum free fatty acid levels is not. Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
New Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
Lefkowitz, R. J., Rajagopal, K., & Whalen, E. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.007 · Cited by 301
Self-citation
Cited by
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3024 · Cited by 825
Self-citationDavenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
GPCR-Mediated Signaling of Metabolites
Husted, A. S., Trauelsen, M., Rudenko, O., Hjorth, S. A., & Schwartz, T. W. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.008 · Cited by 590
Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105800 · Cited by 583
Self-citationKenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis
Sivaprakasam, S., Prasad, P. D., & Singh, N. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.007 · Cited by 571
Therapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 510
Self-citationFunctional Selectivity and Biased Receptor Signaling
Kenakin, T. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173948 · Cited by 505
The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling
Peterson, Y. K., & Luttrell, L. M. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013367 · Cited by 422
Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling
Shukla, A. K., Xiao, K., & Lefkowitz, R. J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.06.003 · Cited by 418
Self-citationMechanisms of Blood–Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids
Fock, E., & Parnova, R. (2023) · Cells · doi:10.3390/cells12040657 · Cited by 385
Endosomes: A legitimate platform for the signaling train
Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., & Bunnett, N. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906541106 · Cited by 373
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Biased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363
Self-citationMetabolite-Sensing G Protein–Coupled Receptors—Facilitators of Diet-Related Immune Regulation
Tan, J. K., McKenzie, C., Mariño, E., Macia, L., & Mackay, C. R. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052235 · Cited by 303
G-Protein–Coupled Receptors in Heart Disease
Wang, J., Gareri, C., & Rockman, H. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.311403 · Cited by 303
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72151 · Cited by 297
Biased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
G protein-coupled receptors for energy metabolites as new therapeutic targets
Blad, C. C., Tang, C., & Offermanns, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3777 · Cited by 273
Lukasova, M., Malaval, C., Gille, A., Kero, J., & Offermanns, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci41651 · Cited by 266
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Parodi, B., Sanna, A., Cedola, A., Uccelli, A., & Kerlero de Rosbo, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655212 · Cited by 20
“Since HCAR2 can also signal through the activation of the proinflammatory ERK MAPK pathway (HCAR2/ERK1/2 pathway) (11), we speculated that activation of this pathway could be responsible for the pro-inflammatory effect of DMF in vivo; we therefore monitored the phosphorylation of ERK1/2 in IEC isolated from EAE-affect…”
Background
Metadata
- Authors
- Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., & Lefkowitz, R. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-05-01
- Volume
- 119
- Issue
- 5
- Pages
- 1312-1321
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2168336490
- Cited by
- 240
- References
- 2
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.